Study guide
26.1 Source Records and Foundational ALCOA Principles
ACRP CCRA Certified Clinical Research Associate Study Guide 2026 Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Exam Format, Eligibility and Registration
1.1 Exam Format, Eligibility and Current References 1.2 Registration, Fees and Candidate Decisions
2 Chapter 2: CRA Responsibilities and Study Planning
2.1 The CRA Role, Data Integrity and Product Oversight 2.2 Official Blueprint and Study Strategy
3 Chapter 3: Protocols, Endpoints and Trial Design
3.1 Protocol Elements and Endpoint Hierarchy 3.2 Endpoint Interpretation and Eligibility Rationale 3.3 Eligibility Verification and Trial Designs
4 Chapter 4: Bias Control, Blinding and Product Information
4.1 Bias, Randomisation and Comparator Controls 4.2 Unblinding and Investigator Brochure Content 4.3 Reference Safety Information and IB Updates
5 Chapter 5: Estimands and Device Instructions
5.1 Estimands and Intercurrent Events 5.2 Device Instructions, Configuration and Training
6 Chapter 6: Ethical Foundations and Independent Oversight
6.1 Ethical Foundations and the 2024 Declaration of Helsinki 6.2 Vulnerability, Voluntariness and Compensation 6.3 IRB/IEC Composition and Independent Review
7 Chapter 7: Ethics Communication and Informed Consent
7.1 Ethics Reporting, Approval Status and Version Control 7.2 Informed Consent Information and Meaningful Choice 7.3 Consent Documentation, Special Circumstances and Updates
8 Chapter 8: Recruitment, Retention and Confidentiality
8.1 Ethical Eligibility, Recruitment and Retention 8.2 Privacy, Confidentiality and Appropriate Access
9 Chapter 9: Safety Definitions and Classification
9.1 Adverse Event Definitions and Actual Life-Threatening Risk 9.2 Seriousness, Severity and Medical Importance 9.3 Causality, Expectedness and Reference Safety Information
10 Chapter 10: Safety Detection, Reporting and Oversight
10.1 Detecting Events, AESIs and Collection Windows 10.2 Expedited Reporting and the Sponsor Awareness Clock 10.3 Immediate Site Reporting and Independent Safety Oversight
11 Chapter 11: Follow-Up, Adherence and Conflicts
11.1 Safety Communications, Reconciliation and Follow-Up 11.2 Adherence, Discontinuation and Participant Choice 11.3 Conflicts of Interest and Prorated Payments
12 Chapter 12: Development Stages and Product Management
12.1 Nonclinical Background and Human Pharmacology 12.2 Exploratory, Confirmatory and Therapeutic-Use Studies 12.3 Product Storage, Labelling and Excursion Response
13 Chapter 13: Accountability, Integrity and Regulatory Status
13.1 Product Accountability and Adherence Calculations 13.2 Potential Fraud, Misconduct and Evidence Preservation 13.3 Submissions, Authorisation Status and Trial Reporting
14 Chapter 14: Current GCP Principles and Delegation
14.1 The Eleven Current GCP Principles 14.2 Proportionality and Investigator Oversight 14.3 Delegation, Qualifications and Task Authority
15 Chapter 15: Oversight, Protocol Control and Amendments
15.1 Clinical Oversight and Immediate-Hazard Changes 15.2 Deviation Classification and Resolution
16 Chapter 16: Implementation and Trial Responsibilities
16.1 Amendment Implementation and Communication 16.2 Sponsor, Investigator and Service-Provider Roles
17 Chapter 17: Quality Planning, Root Causes and CAPA
17.1 Quality Planning and Risk Management 17.2 Root Cause Analysis and CAPA Design 17.3 CAPA Implementation and Effectiveness Verification
18 Chapter 18: Risk Assessment and Monitoring Methods
18.1 Risk Assessment and Centralised Surveillance 18.2 Monitoring Methods and Source Review
19 Chapter 19: Quality Metrics, Plans and Communication
19.1 KRIs, Acceptable Ranges and Trial-Level Quality 19.2 Monitoring Plans, Co-Monitoring and Communication
20 Chapter 20: Site Qualification and Readiness
20.1 Site Qualification and Investigator Capacity 20.2 Recruitment Feasibility and Evidence-Based Site Selection 20.3 Site Readiness and Activity-Specific Release
21 Chapter 21: Initiation, Equipment and Supplies
21.1 Initiation Training and Readiness Walkthroughs 21.2 Equipment, Maintenance and Study Supplies
22 Chapter 22: Samples, Diagnostics and Financial Feasibility
22.1 Specimens, Diagnostic Results and Rater Quality 22.2 Contracts, Budgets and Operational Feasibility
23 Chapter 23: Interim Monitoring and Reporting
23.1 Interim Visit Preparation and Consent Review 23.2 Monitoring Eligibility, Safety and Products 23.3 Investigator Debrief and Monitoring Reports
24 Chapter 24: Essential Records, Audits and Findings
24.1 Essential Records and Site/Sponsor Reconciliation 24.2 Version History, Resolution Evidence and Noncompliance 24.3 Audits, Inspections and Closure Planning
25 Chapter 25: Close-Out, Retention and Destruction
25.1 Close-Out, Archiving and Continuing Obligations 25.2 Retention, Destruction and Long-Term Access
26 Chapter 26: Source Records and Good Documentation
26.1 Source Records and Foundational ALCOA Principles 26.2 Good Documentation, Completeness and Corrections 26.3 Source Access, Certified Copies and Context
27 Chapter 27: Electronic Systems, Metadata and Queries
27.1 EDC Design and Fit-for-Purpose Systems 27.2 Audit Trails, Electronic Outcomes and Device Choice 27.3 Queries, Coding and Supported Clinical Meaning
28 Chapter 28: Dataset Finalisation and Critical Data
28.1 Safety Reconciliation and Dataset Finalisation 28.2 Critical Data, Acquisition Tools and Interim Findings
26.1 Source Records and Foundational ALCOA Principles
Key Takeaways Explain This Topic AI
Source records can be paper, electronic or suitable certified copies.
A CRF can be source when it is the first defined capture of the observation.
Attribution and readable, traceable corrections support reliable records.
Last updated: October 2026
Source Records and Foundational ALCOA Principles
Note
Under the International Council for Harmonisation (ICH) E6 Good Clinical Practice (GCP) guideline, reliable clinical trial data depend fundamentally on the integrity, verifiability, and pedigree of source documentation. In clinical research, regulatory authorities operate under an uncompromising evidentiary doctrine: "If it is not documented, it did not happen; if it is not documented in the source, it cannot be verified in the trial." The Clinical Research Associate (CRA) serves as the primary operational safeguard verifying that trial data entered into case report forms reflect verifiable, original clinical observations that adhere to the ALCOA+ data integrity principles.
Clinical trials are conducted to generate scientifically robust, ethically unassailable evidence of therapeutic safety and efficacy. When regulatory agencies such as the US Food and Drug Administration (FDA), European Medicines Agency (EMA), or Pharmaceuticals and Medical Devices Agency (PMDA) evaluate a Marketing Authorization Application (MAA) or New Drug Application (NDA), their inspectors do not inspect the final marketing claims in isolation.
Instead, inspectors reconstruct the entire clinical trial from primary source records. If primary source documents are fragmented, fabricated, illegible, or unverified, the reliability of the conclusions is threatened, regardless of how promising the treatment appears.
Source Data vs. Source Documents (ICH E6(R3))
A foundational source-record distinction is the operational and regulatory definition separating Source Data from Source Documents under ICH E6:
The Relationship Between Source Records and Case Report Forms (CRFs)
Under ICH E6(R3), the Case Report Form (CRF) is defined as a printed, optical, or electronic document designed to record all of the protocol-required information to be reported to the sponsor on each trial subject.
Crucially, a CRF can be a source record when data are first captured there . The CRF is a reporting instrument intended to capture transcribed summaries of primary clinical events. However, where the source/data-capture arrangement defines direct capture onto a dedicated paper worksheet or electronic form without prior independent medical charting (e.g., a visual analog pain scale completed directly on an electronic tablet), that specific form is designated as direct data entry or eSource .
Where direct data entry is permitted, the protocol and trial monitoring plan must explicitly document that the CRF page serves as its own primary source document.
Common Examples of Primary Source Documents
In hospital, outpatient, and academic research settings, source documents encompass diverse media:
Electronic Health Record (EHR) Progress Notes: Attending physician notes, sub-investigator progress narratives, consultation reports, and discharge summaries.
Nursing Flowsheets & Vital Sign Records: Bedside observation logs, infusion administration records, triage sheets, and timed post-dose monitoring logs.
Diagnostic Instrument Outputs: 12-lead Electrocardiogram (ECG) rhythm strips, Spirometry pulmonary function curves, Polysomnography traces, and Holter monitor digital recordings.
Clinical Diagnostic Laboratory Reports: Automated hematology, clinical chemistry, coagulation printouts, and pathology/histology biopsy reports.
Investigational Pharmacy Records: Master Drug Accountability Logs (DAL), individual Subject Dispensing Logs, temperature monitoring tapes, and compounding records.
Participant-Generated Records: Paper symptom diaries, electronic patient-reported outcome (ePRO) logs, and quality-of-life survey forms.
Medical Imaging Files: Digital Imaging and Communications in Medicine (DICOM) optical discs or Picture Archiving and Communication System (PACS) servers for CT scans, MRIs, and PET scans.
The Evolution of ALCOA and ALCOA+ Principles
ALCOA+ is a useful data-integrity mnemonic: attributable, legible, contemporaneous, original and accurate, extended to complete, consistent, enduring and available. Terminology varies; the ECO uses ALCOA+. Do not memorise an invented claim that one universally defined nine-item ALCOA+ regulation exists. Apply the attributes to the data's full lifecycle.
- Deep-Dive Analysis of ALCOA+ Elements
- Attributable (A)
Every observation, measurement, clinical assessment, and record modification must be traceable to the specific individual who performed the assessment and authored the entry. In paper documentation, attribution requires an identifiable handwritten signature or registered initials accompanied by the calendar date and, where applicable, time where relevant. In electronic systems, attribution is established through unique, non-shared user credentials linked to immutable, time-stamped system logs.
DOA Log Verification: Verify appropriate authorisation, qualifications and training for the activity; use proportionate delegation documentation rather than assuming every routine-care activity must appear on one log.
Prohibition of Proxy Documentation: Coordinators or nurses may never sign for a physician, nor may staff enter data using another colleague's login credentials.
Legible (L)
Clinical records must remain decipherable, readable, and comprehensible for decades following trial completion. Illegible handwriting, blurred thermal paper, low-resolution scans, or compressed digital files violate this principle.
Compliant Error Correction Standards: When an error occurs on a paper source document, the correction must follow strict Good Documentation Practice (GDP):
Draw a single strike-through line through the erroneous text (e.g., 128/80 ).
Ensure the original erroneous entry remains completely visible and readable .
Enter the correct value adjacent to the strike-through (e.g., 138/80).
Initial and date the correction contemporaneously.
Document a brief reason for the change if the reason is not self-evident (e.g., "transcription error" or "wrong subject chart").
Strictly Prohibited Practices: Using opaque correction fluid ("white-out"), correction tape, heavy scribbling, obliterating markers, erasable pens, erasers, or overwriting numbers (such as converting a '3' into an '8') is considered potential evidence of fraudulent alteration.
Official sources
Checked October 18, 2026: ICH E6(R3), Principles and Annex 1 , ICH E9(R1) .